AU2018359013A1 - Pharmaceutical compositions for controlling and/or reducing the progression of myopia - Google Patents

Pharmaceutical compositions for controlling and/or reducing the progression of myopia Download PDF

Info

Publication number
AU2018359013A1
AU2018359013A1 AU2018359013A AU2018359013A AU2018359013A1 AU 2018359013 A1 AU2018359013 A1 AU 2018359013A1 AU 2018359013 A AU2018359013 A AU 2018359013A AU 2018359013 A AU2018359013 A AU 2018359013A AU 2018359013 A1 AU2018359013 A1 AU 2018359013A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
approximately
treating
atropine
ophthalmic device
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018359013A
Other languages
English (en)
Inventor
Minas Theodore Coroneo
Monica JONG
Amandeep Kaur
Padmaja Rajagopal Sankaridurg
Earl Leo Smith Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brien Holden Vision Institute Ltd
Original Assignee
Brien Holden Vision Institute Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brien Holden Vision Institute Ltd filed Critical Brien Holden Vision Institute Ltd
Publication of AU2018359013A1 publication Critical patent/AU2018359013A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018359013A 2017-11-03 2018-11-02 Pharmaceutical compositions for controlling and/or reducing the progression of myopia Abandoned AU2018359013A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762581112P 2017-11-03 2017-11-03
US62/581,112 2017-11-03
PCT/AU2018/051187 WO2019084621A1 (en) 2017-11-03 2018-11-02 Pharmaceutical compositions for controlling and/or reducing the progression of myopia

Publications (1)

Publication Number Publication Date
AU2018359013A1 true AU2018359013A1 (en) 2020-05-21

Family

ID=66331107

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018359013A Abandoned AU2018359013A1 (en) 2017-11-03 2018-11-02 Pharmaceutical compositions for controlling and/or reducing the progression of myopia

Country Status (10)

Country Link
US (1) US20200345633A1 (enExample)
EP (1) EP3703691A4 (enExample)
JP (2) JP2021501803A (enExample)
KR (1) KR20200088824A (enExample)
CN (3) CN111787920A (enExample)
AU (1) AU2018359013A1 (enExample)
CA (1) CA3081593A1 (enExample)
SG (1) SG11202004005RA (enExample)
TW (1) TW201932104A (enExample)
WO (1) WO2019084621A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3763280A1 (de) * 2019-07-11 2021-01-13 Carl Zeiss Vision International GmbH Bestimmung einer veränderung eines refraktionsfehlers eines auges
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
CN114306331B (zh) * 2020-10-10 2023-07-18 远大生命科学(武汉)有限公司 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途
WO2022259211A1 (en) * 2021-06-11 2022-12-15 Brien Holden Vision Institute Limited Ophthalmic compositions and/or methods for presbyopia, mydriasis and/or ocular discomfort management
WO2025259674A1 (en) * 2024-06-11 2025-12-18 Ads Therapeutics Llc Compositions and methods for delivery of pharmaceutical actives
CN119139472A (zh) * 2024-09-26 2024-12-17 温州医科大学附属眼视光医院 腺苷信号阻滞剂在制备治疗弱视和改善视觉可塑性的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG61430B1 (bg) * 1994-03-23 1997-08-29 Иван ХРИСТОВ антиастматично лекарствено средство
WO1995033451A1 (en) * 1994-06-06 1995-12-14 Warner-Lambert Company Non-sedating allergy sinus medication
US5574044A (en) * 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
CA2276287C (en) * 1997-01-06 2007-10-30 Klaus Trier Aps Screening method for compounds active in treating myopia and hypermetropia
ES2752008T3 (es) * 2009-10-30 2020-04-02 Intratus Inc Métodos y composiciones para la liberación sostenida de fármacos
WO2012161655A1 (en) * 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
JP5993620B2 (ja) * 2011-06-01 2016-09-14 ロート製薬株式会社 点眼剤
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition

Also Published As

Publication number Publication date
CN118403054A (zh) 2024-07-30
CN111787920A (zh) 2020-10-16
EP3703691A4 (en) 2021-07-28
US20200345633A1 (en) 2020-11-05
CA3081593A1 (en) 2019-05-09
TW201932104A (zh) 2019-08-16
JP2023179418A (ja) 2023-12-19
KR20200088824A (ko) 2020-07-23
CN118384160A (zh) 2024-07-26
JP2021501803A (ja) 2021-01-21
WO2019084621A1 (en) 2019-05-09
SG11202004005RA (en) 2020-05-28
EP3703691A1 (en) 2020-09-09

Similar Documents

Publication Publication Date Title
US20250049761A1 (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
US20200345633A1 (en) Pharmaceutical Compositions for Controlling and/or Reducing the Progression of Myopia
JP7795555B2 (ja) 近視を治療するための方法及び薬物組成物
EP2588096A1 (en) Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease
CN115634226B (zh) 一种采用长春西汀治疗近视的方法
HK40039952A (en) Pharmaceutical compositions for controlling and/or reducing the progression of myopia
Galeana Prospective Interventional Non-Comparative Non-Randomized Clinical Study of A Topical Synergic Compound to Mitigate Presbyopia Effects
HK40011588A (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
HK40086794B (en) Method for treating myopia by vinpocetine
NZ623037B2 (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
HK1198426B (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted